不同剂量厄贝沙坦治疗糖尿病肾病的临床疗效观察

Effect observation of treated diabetic nephropathy by different doses irbesartan

目的对不同剂量厄贝沙坦治疗糖尿病肾病(DN)患者疗效进行比较。方法将56例糖尿病肾病患者随机分为治疗组(300mg/d)和对照组(150mg/d)各28例,观察治疗前及治疗3个月后血压、血肌苷(Scr)、血尿素氮(BUN)、血清钾(K)及尿微量白蛋白的变化。结果两组患者治疗后血压都有降低,但差异无统计学意义(P>0.05),尿白蛋白治疗后均显著下降(P<0.01),治疗组下降更为显著(P<0.05)。结论大剂量厄贝沙坦(300mg/d)降尿白蛋白优于小剂量厄贝沙坦(150mg/d),对DN患者有独立于血压之外的肾脏保护作用,安全性好。

Objective Treatment of different doses of irbesartan in diabetic nephropathy（DN） patient outcomes were compared.Methods Totally 56 patients with diabetic nephropathy were randomly divided into treatment group（300mg/d） and control group（150mg/d） each 28 cases,observed before and after 3 months of treatment blood pressure,blood creatinine（Scr）,blood urea nitrogen（BUN）,serum potassium（K） and urinary albumin changes.Results The patients had lower blood pressure after treatment,but the difference was not statistically significant（P0.05）,urinary albumin were significantly decreased after treatment（P0.01）,the treatment group decreased more significantly（P0.05）.Conclusions Large dose of irbesartan（300mg/day） reduced urinary albumin is superior to low dose of irbesartan（150mg/day）,independent of the DN patients have renal protective effects beyond blood pressure and good security.